Evidence map›Paper›PMID 28477386›Full record

ArticleBritish journal of pharmacology2018

Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states.

Roger L Papke, Clare Stokes, M Imad Damaj, Ganesh A Thakur, Khan Manther, Millet Treinin, Deniz Bagdas, Abhijit R Kulkarni, Nicole A Horenstein

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Modulation of the mammalian GABABritish journal of pharmacology · 2022
    Article
  10. Review
  11. Stable desensitization of αEuropean journal of pharmacology · 2021
    Article
  12. Therapeutic Targeting ofPharmacological reviews · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Macroscopic and Microscopic Activation ofMolecular pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Roger L PapkeDepartment of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA.ORCID 0000-0002-4468-8658
Clare StokesDepartment of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA.
M Imad DamajDepartment of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.
Ganesh A ThakurDepartment of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Khan MantherDepartment of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA.
Millet TreininDepartment of Medical Neurobiology, Hadassah Medical School, Hebrew University, Jerusalem, Israel.ORCID 0000-0002-2625-2850
Deniz BagdasDepartment of Pharmacology and Toxicology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA, USA.
Abhijit R KulkarniDepartment of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.
Nicole A HorensteinDepartment of Chemistry, University of Florida, Gainesville, FL, USA.ORCID 0000-0001-7505-1230
University of Florida · USNortheastern University · USBursa Uludağ Üni̇versi̇tesi̇ · TRHadassah Medical Center · ILVirginia Commonwealth University Medical Center · US

Funding

Targeting of Alpha7 nAChR for therapeutic effectsR01GM057481 · NIGMS · UNIVERSITY OF FLORIDA · PI PAPKE, ROGER L · 2000 to 2023
$7.6M
(PQ9) Mitigation of chemotherapy induced peripheral neuropathyR01CA206028 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DAMAJ, M. IMAD, GEWIRTZ, DAVID A. · 2016 to 2020
$1.7M
NCI NIH HHS R01 CA206028NIGMS NIH HHS R01 GM057481
6 · The paper itself

Abstract

background and purposeGAT107 ((3aR,4S,9bS)-4-(4-bromo-phenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta-[c]quinoline-8-sulfonamide) is a positive allosteric modulator (PAM) and agonist of α7 nicotinic acetylcholine receptors (nAChRs)that can cause a prolonged period of primed potentiation of acetylcholine responses after drug washout. NS6740 is a silent agonist of α7 nAChRs that has little or no efficacy for activating the ion channel but induces stable desensitization states, some of which can be converted into channel-active states by PAMs. Although GAT107 and NS6740 appear to stably induce different non-conducting states, both agents are effective treatment for inflammation and inflammatory pain models. We sought to better understand how both of these drugs that have opposite effects on channel activation could regulate signal transduction. EXPERIMENTAL APPROACH: Voltage-clamp experiments were conducted with α7 nAChRs expressed in Xenopus oocytes. KEY

resultsLong-lived sensitivity to a PAM or to an agonist was produced by NS6740 or GAT107 respectively. With sequential applications, these two drugs induced varying levels of persistent activation, which is a unique condition for a receptor that is known for rapid desensitization. The non-conducting states induced by NS6740 or GAT107 differ in their sensitivity to an α7 nAChR-selective antagonist and in how effectively they promote current. CONCLUSIONS & IMPLICATIONS: Our data suggest that the persistent currents represent a dynamic interconversion between different stable desensitized states and the PAM-inducible conducting states. However, the similarity of NS6740 and GAT107 effects on inflammation and pain suggests that the different stable non-conducting states have common activity on signal transduction. LINKED ARTICLES: This article is part of a themed section on Nicotinic Acetylcholine Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.11/issuetoc.

Indexed as

Allosteric Regulationalpha7 Nicotinic Acetylcholine ReceptorAnimalsAzabicyclo CompoundsFemaleFuransQuinolinesSulfonamidesXenopus laevis1,4-diazabicyclo(3.2.2)nonan-4-yl(5-(3-(trifluoromethyl)phenyl)furan-2-yl)methanone4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinoline-8-sulfonamidealpha7 Nicotinic Acetylcholine ReceptorAzabicyclo CompoundsFuransQuinolinesSulfonamides

Identifiers

PMID28477386
PMCPMC5979752
OpenAlexW2884240656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.